PrimeRFP SCOUT · Federal Contract Recompete Brief

36C77021N0214Pharmaceutical - naloxone 4mg NASAL SPRAY — Adapt Pharma Inc

Adapt Pharma Inc holds $753K across 16 federal awards, concentrated at Department of Homeland Security (DHS). This PIID sits alongside 1 related award in the incumbent pipeline.

National Cmop Office (36C770)
Awarding office
Adapt Pharma Inc
Recipient
—
Estimated value
6505
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Federal
Contract number36C77021N0214
Also listed as36C770-21-N-0214
AgencyNational Cmop Office (36C770)
Awarding officeNational Cmop Office (36C770)
Awarding agencyDepartment of Veterans Affairs (VA)
Funding agencyDepartment of Veterans Affairs (VA)
IncumbentAdapt Pharma Inc
UEIQ1MZNNSQUJ53
PSC6505

PHARMACEUTICAL - NALOXONE 4MG NASAL SPRAY SOLUTION FOR HINES CMOP is a federal award for National Cmop Office (36C770) held by Adapt Pharma Inc. Estimated value —.

PHARMACEUTICAL - NALOXONE 4MG NASAL SPRAY SOLUTION FOR HINES CMOP

Bonuses end Sept 30

Want the durability read on 36C77021N0214? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Adapt Pharma Inc — $753K obligated across 16 awards (firm-wide, all agencies) · lead buyer Department of Homeland Security (DHS).

% of firm-wide obligated ($753K) · all agencies
Department of Homeland Security (DHS)$473K · 63%Department of State (DOS)$285K · 38%

Related awards

Same incumbent
19AQMM26P0604
NARCAN NASAL SPRAY DEVICES
$285K
Jun 1, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Explore more pipelines →

Frequently asked questions

What is contract 36C77021N0214?

36C77021N0214 (Pharmaceutical - naloxone 4mg NASAL SPRAY) is a National Cmop Office (36C770) award with an estimated value of —, currently held by Adapt Pharma Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C770-21-N-0214?

36C770-21-N-0214 is the dashed form of PIID 36C77021N0214 (Pharmaceutical - naloxone 4mg NASAL SPRAY), held by Adapt Pharma Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C77021N0214?

National Cmop Office (36C770) awarded 36C77021N0214 to Adapt Pharma Inc.

Who is the incumbent on 36C77021N0214?

Adapt Pharma Inc is the incumbent with $753K across 16 related awards in SCOUT’s public footprint.

When does Adapt Pharma Inc’s 36C77021N0214 come up for recompete?

SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 36C77021N0214? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthly
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/36C77021N0214